Organic Active Ingredients TRIZ Cases

A bispecific engager links dendritic cells to tumor markers to boost anti-cancer immunity.

RNA aptamer targets CEA linkage region, resolving antibody immunogenicity and stability issues while inhibiting liver metastasis.

Nano-dry-melting aqueous nanoparticle suspensions creates amorphous solid dispersions without organic solvents or thermal degradation.

Mesoporous silica particles sequester pathogenic proteins in cerebrospinal fluid, delaying neurodegenerative disease progression and increasing survival rates.

Optimizing the tip diameter to 20 µm and aspect ratio to 1–5 maintains structural integrity while enabling efficient drug delivery.

Homogeneous phospholipid bilayers catalytically promote protein refolding and increase stability.

Formula I and II compounds mitigate radiation-induced apoptosis through cellular uptake saturation.

Biguanide dimers chelate mitochondrial copper to inhibit alpha-ketoglutarate production, resolving moderate potency limits in inflammatory disease treatment.

Dual inhibition of bromodomain and DNA methylation pathways overcomes acquired resistance in cancer therapy, restoring drug efficacy.

Fluorinated benzene structure enhances solubility and metabolic stability while reducing toxicity in cancer therapy.

Menthyl carbamate compounds lighten skin and hair without cytotoxicity or instability issues associated with traditional hydroquinone agents.

Hexylene glycol suspends mometasone furoate to reduce skin irritancy while maintaining therapeutic efficacy and hydration.

Probiotic bacteria induce split anergy in natural killer cells, balancing enhanced anti-tumor immunity with reduced unwanted inflammation.

Dual Factor XIa and kallikrein inhibitors address complex blood coagulation pathways to prevent thrombosis.

Conjugating GBS serotype III oligosaccharides with carrier proteins creates immunogenic compositions.

A coenzyme Q10 microemulsion uses specific emulsifiers to form a thermodynamically stable system with 20-80 nm particles.

Pyridine macrocycle compounds inhibit apoptosis signal-regulating kinase 1 to treat neurodegenerative and cardiovascular disorders.

Consolidating multiple coating steps into one fluid bed coater improves mesalamine pellet reproducibility.

Covalent inhibitors bind cysteine residues at position 12, locking the switch II domain to overcome low inhibition effectiveness of small molecules.

A pharmaceutical composition containing a specific imidazopyrazinone compound disrupts YAP/TAZ-TEAD protein interactions.

Anti-protease nexin-1 antibodies neutralize the anticoagulant inhibitor to enhance thrombin generation and bypass factor VIII resistance.

A glycogen and polysaccharide mixture provides sustained active ingredient release through diffusion and erosion mechanisms.

Novel cationic lipids form lipid nanoparticles to protect nucleic acids from plasma nuclease digestion while facilitating efficient intracellular delivery.

CRISPR-mediated PTGIR knockout in CD8 T-cells eliminates prostacyclin signaling, restoring anti-tumor activity suppressed by tumor-derived prostanoids.

4-Alkenyl and 4-alkynyl phenethylamine derivatives interact with serotonin 5-HT2A receptors to induce psychoactive effects.

Formula I compounds reduce viral load by modifying chemical structures to optimize antiviral activity while maintaining patient safety.

Optimized crystallization parameters transform unstable ruxolitinib free base into defined dihydrate crystals, resolving purity and hygroscopicity trade-offs.

Modified ganciclovir derivatives reduce toxic side effects while maintaining antiviral efficacy against HCMV in transplant patients.

Increasing miR-18b expression suppresses apoptosis and recovers calcium signaling to address underlying dysregulation in gene mutation-induced muscle diseases.

Polydeoxyribonucleotides treat inflammatory bowel disease by activating A2A receptors, reducing side effects from conventional therapies.

Novel bicyclic tetrahydrofuran derivatives protect chain-terminating nucleotides from enzymatic excision.

Formula I compounds selectively inhibit CDK19 over CDK8, resolving the contradiction between anti-cancer efficacy and gastrointestinal side effects.

Dual-sensitive vesicles eliminate excess hydrogen peroxide during glucose oxidation, preventing localized inflammation while delivering insulin.

Lipid-modified tc-DNA oligomers bind serum albumin to enhance bioavailability and reduce toxicity while promoting exon 51 skipping.

Chimeric small molecules recruit endogenous antibodies to prostate cancer cells, inducing cytotoxicity while minimizing treatment costs and side effects.

Local quality design of cationic binding sites on a hydrophilic shell reduces cellular toxicity and bleeding risks compared to heparin.

Carboxyl-modified polyamines reduce in vivo toxicity by neutralizing charge while maintaining endosomal buffering to deliver siRNA to liver cells.

Bioluminescent luciferase activates halorhodopsin to silence refractory seizures without external light sources.

Dispersing TMC278 in water-soluble polymers yields a supersaturated solution that overcomes poor drug solubility for flexible pediatric dosing.

Using the tunnel barrier as an etch stop prevents electrical shorting from inadequate vertical separation in MRAM fabrication.

Convergent reductive amination synthesizes ferroquine from aldehyde-amino ferrocene and 7-chloroquinolin-4-amine in a streamlined one-pot sequence.

RNA-encoded IL2 variants fused to human serum albumin deliver steady cytokine release via lipid nanoparticles.

Mast cell stabilizing compounds reduce inflammatory mediator release, balancing immune response and controlling hypercytokinemia during viral infections.

A fluid delivery apparatus uses a bias assembly to apply a two-stage force profile to a plunger component for precise medicament administration.

A DGAT1 inhibitor induces sebaceous gland atrophy to reduce sebum production.

Polymer-modified opioid prodrugs resist systemic exposure and prevent euphoric states by limiting oral absorption in the gastrointestinal tract.

Inhaled p38 MAPK inhibitors with optimized pharmacokinetics extend lung retention, reducing systemic side effects while treating COPD and asthma.

A sublingual formulation combines fentanyl and naloxone with a terpene to deliver rapid pain relief.

Indazole and azaindazole compounds inhibit LRRK2 kinase activity to treat neurodegenerative disorders.

Heat-moisture treatment at 105°C to 135°C modifies pea starch crystalline structure, increasing slowly digestible fraction while managing glycemic response.

Combining rAAV progranulin delivery with immunosuppressants overcomes blood-brain barrier limits and refractory neurological symptoms in GRN mutation patients.

Segmented iron sugar shells prime intestinal transporters while laxative sugars counteract constipation from oral iron supplements.

Cas9-sgRNA delivery enables rapid in vivo gene deletion in hematopoietic stem cells.

Ethyl modifications at the guanine N2 position increase translation yield while reducing immunogenicity.

Enzymatic hydrolysis and anion-exchange purification yield fish swim bladder-derived heparin-like mucopolysaccharide that inhibits angiogenesis.

Segmented heterocyclic compounds inhibit FGFR4 selectively to reduce toxicity from non-specific kinase inhibition.

Oral exopolysaccharides inhibit CEACAM-1 expression to prevent secondary bacterial infections without antibiotic resistance.

Cyano-substituted indoles target the LSD1 catalytic domain to achieve potent inhibition while minimizing off-target effects on monoamine oxidase enzymes.

Bicyclic carboxamide compounds inhibit ALK kinase activity to reduce tumor volume in cancers driven by oncogenic ALK signaling.

In situ formed ocular implants provide sustained drug release, reducing injection frequency and tissue trauma.

A six-gene biomarker panel predicts ovarian cancer recurrence risk and platinum therapy resistance.

Benzimidazolone compounds bind the BCL6 BTB domain to inhibit protein activity and arrest malignant B cell proliferation.

Pneumatic atomization creates sub-6-micron nicotine aerosols, resolving dry powder agglomeration and heat degradation issues in inhalers.

Siliceous spicules from Spongilla penetrate the stratum corneum to deliver dermal fillers, avoiding needle injection pain and anxiety.

Substituted 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides selectively inhibit PARP-1 enzyme activity.

Administering miR-181b nucleic acids downregulates NF-kB signaling to reduce leukocyte adhesion without broad systemic side effects.

Novel imidazole therapeutic agents combat antibiotic-resistant bacterial infections by modifying chemical structures to overcome resistance mechanisms.

Oxymethyl-modified quercetin derivatives inhibit tumor cell proliferation and induce apoptosis through targeted structural modifications.

Replacing mechanical compression with radiofrequency heating and sintering reduces disintegration time while maintaining tablet hardness.

Formula I bicyclic heteroaryl compounds target the underlying cause of Huntington's disease, addressing the lack of effective small molecule therapies.

Trinucleotide cap analogs reduce dsRNA-induced immune responses while enhancing mRNA translation efficiency.

Specific calcium carbonate particle size distribution resolves low absorption efficiency to improve bone strength.

Small molecule compounds activate Wnt signaling to promote cochlear supporting cell self-renewal and hair cell differentiation.

Buprenorphine targets kappa opioid receptors to reduce self-injurious behavior in emotionally unstable personality disorder.

Pre-solubilized HCA salt in a water-glycerol capsule avoids lactonization and poor dispersion, ensuring complete bioavailability.

Crystalline solifenacin succinate prevents aggregation during direct compression, ensuring content uniformity and chemical stability.

Thioether-piperidinyl compounds antagonize orexin receptors, resolving the lack of effective treatments for insomnia and neurological disorders.

A chitosan salt hemostatic powder forms a robust gel clot to stem blood flow without requiring skilled application.

Segmented mixing prevents gel-like mass formation during the preparation of oral film dosage forms, ensuring uniform dispersion of amine actives.

Combining enteric amino acids with indigestible polysaccharides promotes bifidobacteria proliferation in the lower gastrointestinal tract.

Encapsulating T3 in bioabsorbable polymers stabilizes the drug for room temperature storage and rapid emergency administration.

In situ virus-like particle administration overcomes ineffective late-stage treatments by inducing systemic anti-tumor immunity without inflammatory damage.

Equal parts granulated sugar and hydrogel biomaterial promote epithelialization while removing fibrin, slough, and biofilm from chronic non-healing wounds.

Selective delta receptor activation by a morphinan derivative provides analgesia while avoiding respiratory depression linked to mu receptor agonists.

Converting the STAT3 inhibitor NSC-74859 to a disodium salt resolves poor water solubility while maintaining cancer treatment efficacy.

Deuterium substitution at specific ring positions slows CYP-mediated metabolism, reducing toxic metabolite formation and improving therapeutic safety.

Assessing IKZF3 and IFI27 biomarkers predicts clinical sensitivity, eliminating months of waiting for efficacy data to establish accurate therapeutic response.

Tricyclic compounds modulate MetAP2 to treat obesity without harmful side effects from traditional pharmacotherapies.

Standardized plant extract combination reduces cancer-related fatigue symptoms while minimizing side effects from conventional palliative treatments.